{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T09:53:05Z","timestamp":1694685185021},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,8,30]],"date-time":"2008-08-30T00:00:00Z","timestamp":1220054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00108-008-2118-8","type":"journal-article","created":{"date-parts":[[2008,9,26]],"date-time":"2008-09-26T15:37:42Z","timestamp":1222443462000},"page":"1186-1196","source":"Crossref","is-referenced-by-count":2,"title":["Grundlagen und Management der glukokortikoidinduzierten Osteoporose"],"prefix":"10.1007","volume":"49","author":[{"given":"H.S.","family":"Willenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,30]]},"reference":[{"key":"2118_CR1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1046\/j.1365-2036.2002.01247.x","volume":"16","author":"Abitbol","year":"2002","unstructured":"Abitbol V, Mary JY, Roux C et al.; Groupe D\u2019etudes Therapeutiques des Affections Inflammatoires Digestives (2002) Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 16: 919\u2013927","journal-title":"Aliment Pharmacol Ther"},{"key":"2118_CR2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/rheumatology\/36.2.255","volume":"36","author":"Adachi","year":"1997","unstructured":"Adachi JD, Bensen WG, Bell MJ et al. (1997) Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 36: 255\u2013259","journal-title":"Br J Rheumatol"},{"key":"2118_CR3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44: 202\u2013211","journal-title":"Arthritis Rheum"},{"key":"2118_CR4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","volume":"16","author":"Boutsen","year":"2001","unstructured":"Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteopo-rosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months and calcium alone. J Bone Miner Res 16: 104\u2013112","journal-title":"J Bone Miner Res"},{"key":"2118_CR5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/thx.2003.013839","volume":"59","author":"Campbell","year":"2004","unstructured":"Campbell IA, Douglas JG, Francis RM et al. (2004) Research committee of the british thoracic society five year study of etidronate and\/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and\/or inhaled glucocorticoids. Thorax 59: 761\u2013768","journal-title":"Thorax"},{"key":"2118_CR6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE et al. (2008) Denosumab rheumatoid arthritis study group denosumab treatment effects on structural damage, bone mineral density and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58: 1299\u20131309","journal-title":"Arthritis Rheum"},{"key":"2118_CR7","unstructured":"Dachverband Deutschsprachiger Wissenschaftlicher Gesellschaften f\u00fcr Osteologie (2006) Prophylaxe, Diagnostik und Therapie der glukokortikoid-induzierten Osteoporose. Langfassung. http:\/\/www.lutherhaus.de\/osteo\/leitlinien-dvo\/"},{"key":"2118_CR8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00198-007-0345-9","volume":"18","author":"Duyvendak","year":"2005","unstructured":"Duyvendak M, Naunton M, Atthobari J et al. (2005) Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in the Netherlands 2001\u20132005. Osteoporos Int 18: 1429\u20131433","journal-title":"Osteoporos Int"},{"key":"2118_CR9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/0003-4819-133-7-200010030-00010","volume":"133","author":"LaCroix","year":"2000","unstructured":"LaCroix AZ, Ott SM, Ichikawa L et al. (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 133: 516\u2013526","journal-title":"Ann Intern Med"},{"key":"2118_CR10","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"Lewiecki","year":"2007","unstructured":"Lewiecki EM, Miller PD, McClung MR et al.; AMG 162 Bone Loss Study Group (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22: 1832\u20131841","journal-title":"J Bone Miner Res"},{"key":"2118_CR11","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1001\/archinte.160.19.2917","volume":"160","author":"Naganathan","year":"2000","unstructured":"Naganathan V, Jones G, Nash P et al. (2000) Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density and corticosteroid use. Arch Intern Med 160: 2917\u20132922","journal-title":"Arch Intern Med"},{"key":"2118_CR12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis and therapy. JAMA 285: 785\u2013795","journal-title":"JAMA"},{"key":"2118_CR13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-107-2-319","volume":"107","author":"Pocock","year":"1987","unstructured":"Pocock NA, Eisman JA, Dunstan CR et al. (1987) Recovery from steroid-induced osteoporosis. Ann Intern Med 107: 319\u2013323","journal-title":"Ann Intern Med"},{"key":"2118_CR14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","volume":"14","author":"Rehman","year":"2003","unstructured":"Rehman Q, Lang TF, Arnaud CD et al. (2003) Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14: 77\u201381","journal-title":"Osteoporos Int"},{"key":"2118_CR15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","volume":"69","author":"Reid","year":"2001","unstructured":"Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69: 242\u2013247","journal-title":"Calcif Tissue Int"},{"key":"2118_CR16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H et al. (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14: 801\u2013807","journal-title":"Osteoporos Int"},{"key":"2118_CR17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/keg205","volume":"42","author":"Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H et al. (2003) Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology 42: 743\u2013749","journal-title":"Rheumatology"},{"key":"2118_CR18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00296-003-0361-9","volume":"24","author":"Ringe","year":"2004","unstructured":"Ringe JD, Dorst A, Faber H et al. (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24: 63\u201370","journal-title":"Rheumatol Int"},{"key":"2118_CR19","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028\u20132039","journal-title":"N Engl J Med"},{"key":"2118_CR20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1359\/jbmr.2003.18.5.919","volume":"18","author":"Sambrook","year":"2003","unstructured":"Sambrook PN, Kotowicz M, Nash P et al. (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium and alendronate plus calcium. J Bone Miner Res 18: 919\u2013924","journal-title":"J Bone Miner Res"},{"key":"2118_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00296-004-0496-3","volume":"26","author":"Tascioglu","year":"2005","unstructured":"Tascioglu F, Colak O, Armagan O et al. (2005) The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. Rheumatol Int 26: 21\u201329","journal-title":"Rheumatol Int"},{"key":"2118_CR22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/sj.leu.2403890","volume":"19","author":"Terpos","year":"2005","unstructured":"Terpos E, Mihou D, Szydlo R et al. (2005) The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory\/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL\/osteoprotegerin ratio. Leukemia 19: 1969\u20131976","journal-title":"Leukemia"},{"key":"2118_CR23","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"Van","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP et al. (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48: 3224\u20133229","journal-title":"Arthritis Rheum"},{"key":"2118_CR24","doi-asserted-by":"crossref","unstructured":"Van Staa TP, Leufkens HGM, Abenhaim L et al. (2000 \/ 2005) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol 39: 1383\u20131389 \/ J Bone Miner Res 20: 1487\u20131494","DOI":"10.1093\/rheumatology\/39.12.1383"},{"key":"2118_CR25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1046\/j.1365-2796.2003.01219.x","volume":"245","author":"Vestergaard","year":"2003","unstructured":"Vestergaard P, Olsen ML, Paaske Johnsen S et al. (2003) Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med 245: 486\u2013493","journal-title":"J Intern Med"},{"key":"2118_CR26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67: 277\u2013285","journal-title":"Calcif Tissue Int"},{"key":"2118_CR27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1196\/annals.1353.006","volume":"1073","author":"Willenberg","year":"2006","unstructured":"Willenberg HS, Feldkamp J, Lehmann R et al. (2006) A case of catecholamine-excess and cushing\u2019s syndrome due to a corticotropin-secreting paraganglioma. Ann N Y Acad Sci 1073: 52\u201358","journal-title":"Ann N Y Acad Sci"},{"key":"2118_CR28","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","volume":"343","author":"Wise","year":"2000","unstructured":"Wise R, Connett J, Weinmann G et al. for the Lung Health Study Research Group (2000) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343: 1902\u20131909","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-008-2118-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2118-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:12:09Z","timestamp":1558570329000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-008-2118-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,30]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1007\/s00108-008-2118-8","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,30]]}}}